Free Trial
→ White House to reset Social Security? (From Altimetry) (Ad) Buy PLSE Stock  Free PLSE Stock Alerts

Pulse Biosciences (PLSE) Financials

Pulse Biosciences logo
$17.93 +1.00 (+5.91%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$17.23 -0.70 (-3.90%)
As of 09:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Pulse Biosciences

Annual Income Statements for Pulse Biosciences

This table shows Pulse Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 -54 -42 -59 -64 -50 -47 -38 -26 -9.52 -2.81
Consolidated Net Income / (Loss)		 -54 -42 -59 -64 -50 -47 -38 -26 -9.52 -2.81
Net Income / (Loss) Continuing Operations		 -54 -42 -59 -64 -50 -47 -38 -26 -9.52 -2.81
Total Pre-Tax Income 		-54 -42 -59 -64 -50 -47 -38 -26 -9.52 -4.47
Total Operating Income		 -56 -44 -58 -63 -50 -48 -38 -26 -9.52 -4.47
Total Gross Profit		 0.00 0.00 -11 -0.55 0.00 0.00 0.45 0.25 0.07 0.00
Total Revenue		 0.00 0.00 0.70 1.42 0.00 0.00 0.45 0.25 0.07 0.00
Operating Revenue		 0.00 0.00 0.70 1.42 0.00 - 0.45 0.25 0.07 0.00
Total Cost of Revenue		 0.00 0.00 12 1.97 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 56 44 47 62 50 48 38 26 9.59 4.47
Selling, General & Admin Expense		 24 16 14 19 16 17 20 16 3.42 1.62
Research & Development Expense		 32 28 21 29 26 25 17 9.65 5.51 2.18
Total Other Income / (Expense), net		 2.67 1.36 -0.45 -0.65 0.11 0.98 0.00 0.00 0.00 0.00
Interest & Investment Income		 2.67 1.36 -0.45 -0.65 0.11 0.98 - - - 0.00
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.66
Basic Earnings per Share		 ($0.92) ($0.85) ($1.72) ($2.28) ($2.14) ($2.26) ($2.20) ($1.73) ($0.86) ($0.37)
Weighted Average Basic Shares Outstanding		 58.40M 49.74M 33.94M 27.96M 23.25M 20.75M 17.08M 14.75M 11.01M 7.57M
Weighted Average Diluted Shares Outstanding		 67.27M 55.23M 37.59M 27.96M 23.25M 20.75M 17.08M 14.75M 11.01M 7.57M
Weighted Average Basic & Diluted Shares Outstanding		 67.27M 55.23M 37.59M 27.96M 23.25M 20.75M 17.08M 14.75M 11.01M 7.57M

Quarterly Income Statements for Pulse Biosciences

This table shows Pulse Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -17 -19 -13 -11 -10 -12 -11 -9.91 -9.80 -9.20 -18
Consolidated Net Income / (Loss)		 -17 -19 -13 -11 -10 -12 -11 -9.91 -9.80 -9.20 -18
Net Income / (Loss) Continuing Operations		 -17 -19 -13 -11 -10 -12 -11 -9.91 -9.80 -9.20 -18
Total Pre-Tax Income 		-17 -19 -13 -11 -10 -12 -11 -9.91 -9.80 -9.20 -18
Total Operating Income		 -18 -20 -14 -12 -11 -13 -11 -10 -9.56 -8.75 -18
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -1.30 -8.40
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -0.01 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -0.01 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 1.29 8.40
Total Operating Expenses		 18 20 14 12 11 13 11 10 9.56 7.45 9.63
Selling, General & Admin Expense		 7.73 9.60 5.95 4.50 3.87 4.73 3.78 3.53 3.73 2.58 3.09
Research & Development Expense		 10 11 7.70 7.23 6.74 7.80 7.47 6.70 5.83 4.10 4.52
Total Other Income / (Expense), net		 1.25 0.88 0.98 0.34 0.48 0.60 0.69 0.32 -0.24 -0.45 -0.01
Interest & Investment Income		 1.25 0.88 0.98 0.34 0.48 0.60 0.69 0.32 -0.24 -0.45 -0.01
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.25) ($0.33) ($0.21) ($0.20) ($0.18) ($0.18) ($0.19) ($0.22) ($0.26) ($0.21) ($0.49)
Weighted Average Basic Shares Outstanding		 67.13M 58.40M 61.07M 57.18M 55.17M 49.74M 56.87M 46.09M 37.39M 33.94M 37.16M
Weighted Average Diluted Shares Outstanding		 67.27M 67.27M 61.52M 61.29M 55.23M 55.23M 54.99M 54.90M 37.64M 37.59M 37.23M
Weighted Average Basic & Diluted Shares Outstanding		 67.27M 67.27M 61.52M 61.29M 55.23M 55.23M 54.99M 54.90M 37.64M 37.59M 37.23M

Annual Cash Flow Statements for Pulse Biosciences

This table details how cash moves in and out of Pulse Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 74 -17 33 16 5.56 -44 48 1.30 -1.52 -3.40
Net Cash From Operating Activities		 -36 -33 -47 -54 -35 -34 -24 -11 -8.05 -3.32
Net Cash From Continuing Operating Activities		 -36 -33 -47 -54 -35 -34 -24 -11 -8.05 -3.32
Net Income / (Loss) Continuing Operations		 -54 -42 -59 -64 -50 -47 -38 -26 -9.52 -2.81
Consolidated Net Income / (Loss)		 -54 -42 -59 -64 -50 -47 -38 -26 -9.52 -2.81
Depreciation Expense		 0.51 0.54 0.69 0.48 0.43 0.49 0.65 0.34 0.09 0.05
Amortization Expense		 0.67 0.67 0.67 0.68 0.67 0.15 0.53 0.69 0.67 0.67
Non-Cash Adjustments To Reconcile Net Income		 13 6.44 15 15 10 11 12 13 0.87 0.40
Changes in Operating Assets and Liabilities, net		 2.63 1.53 -4.63 -6.31 2.89 0.79 0.11 0.41 -0.17 -1.63
Net Cash From Investing Activities		 -0.13 -0.12 -0.40 7.56 10 -10 26 -23 -14 -0.09
Net Cash From Continuing Investing Activities		 -0.13 -0.12 -0.40 7.56 10 -10 26 -23 -14 -0.09
Purchase of Property, Plant & Equipment		 -0.13 -0.12 -0.40 -0.44 -0.44 -0.61 -0.28 -2.55 -0.06 -0.09
Net Cash From Financing Activities		 110 16 80 63 31 0.08 45 35 21 0.00
Net Cash From Continuing Financing Activities		 110 16 80 63 31 0.08 45 35 21 0.00
Repayment of Debt		 0.00 -0.01 -0.44 -1.53 0.00 0.00 - - - -
Repurchase of Common Equity		 -0.28 0.00 - - - - - - - -
Issuance of Common Equity		 60 0.40 15 58 30 0.42 45 35 21 0.00
Other Financing Activities, net		 50 16 0.03 4.77 0.96 -0.34 0.38 0.54 - 0.00

Quarterly Cash Flow Statements for Pulse Biosciences

This table details how cash moves in and out of Pulse Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 1.24 39 53 -8.69 -9.48 -6.02 -8.36 4.65 -7.04 -8.02 54
Net Cash From Operating Activities		 -14 -9.14 -9.02 -8.40 -9.78 -6.78 -10 -9.20 -6.57 -7.97 -11
Net Cash From Continuing Operating Activities		 -14 -9.14 -9.02 -8.40 -9.78 -6.78 -10 -9.20 -6.57 -7.97 -11
Net Income / (Loss) Continuing Operations		 -17 -19 -13 -11 -10 -12 -11 -9.91 -9.80 -9.20 -18
Consolidated Net Income / (Loss)		 -17 -19 -13 -11 -10 -12 -11 -9.91 -9.80 -9.20 -18
Depreciation Expense		 0.12 0.12 0.13 0.13 0.13 0.14 0.13 0.14 0.14 0.17 0.17
Amortization Expense		 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17
Non-Cash Adjustments To Reconcile Net Income		 5.63 6.76 2.94 2.02 1.73 3.33 -0.40 1.62 1.89 2.90 7.80
Changes in Operating Assets and Liabilities, net		 -2.64 3.20 0.43 0.67 -1.67 1.52 0.18 -1.21 1.04 -2.00 -0.73
Net Cash From Investing Activities		 -0.05 -0.05 -0.04 -0.03 -0.01 -0.04 -0.02 -0.02 -0.04 -0.04 -0.06
Net Cash From Continuing Investing Activities		 -0.05 -0.05 -0.04 -0.03 -0.01 -0.04 -0.02 -0.02 -0.04 -0.04 -0.06
Purchase of Property, Plant & Equipment		 -0.05 -0.05 -0.04 -0.03 -0.01 -0.04 -0.02 -0.02 -0.04 -0.04 -0.06
Net Cash From Financing Activities		 15 48 62 -0.27 0.31 0.80 2.15 14 -0.43 -0.02 65
Net Cash From Continuing Financing Activities		 15 48 62 -0.27 0.31 0.80 2.17 14 -0.43 -0.02 65
Issuance of Common Equity		 0.35 - 60 - 0.30 - 0.10 0.00 0.29 -0.03 0.04
Other Financing Activities, net		 14 48 2.01 0.01 0.01 0.80 0.31 15 0.19 0.01 0.02

Annual Balance Sheets for Pulse Biosciences

This table presents Pulse Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 132 59 78 59 41 42 71 50 26 14
Total Current Assets		 119 45 62 45 22 26 60 38 17 4.00
Cash & Equivalents		 118 44 61 44 12 6.90 51 3.39 2.09 3.61
Prepaid Expenses		 1.41 0.96 1.01 0.96 1.86 1.01 0.78 0.41 0.27 0.04
Plant, Property, & Equipment, net		 1.16 1.53 1.96 1.53 2.48 2.57 2.17 2.57 0.32 0.33
Total Noncurrent Assets		 12 12 14 12 16 13 8.11 8.77 9.33 10.00
Goodwill		 2.79 2.79 2.79 2.79 2.79 2.79 2.79 2.79 2.79 2.79
Intangible Assets		 1.22 1.89 2.55 1.89 3.88 4.55 5.21 5.88 6.54 7.21
Other Noncurrent Operating Assets		 7.84 7.62 8.43 7.62 9.80 5.61 0.10 0.10 0.00 -
Total Liabilities & Shareholders' Equity		 132 59 78 59 41 42 71 50 26 14
Total Liabilities		 18 15 80 15 18 11 4.31 3.83 1.02 0.66
Total Current Liabilities		 10 6.71 5.98 6.71 7.59 4.46 3.11 2.21 1.02 0.66
Accounts Payable		 1.67 1.84 1.57 1.84 1.72 1.96 1.27 0.78 0.27 0.26
Accrued Expenses		 7.03 3.81 2.60 3.81 5.33 2.50 1.42 1.03 0.75 0.40
Other Current Liabilities		 1.36 1.06 0.90 1.06 0.54 0.00 - - - -
Total Noncurrent Liabilities		 7.54 8.09 74 8.09 11 6.72 1.20 1.61 0.00 0.00
Other Noncurrent Operating Liabilities		 7.54 8.09 9.14 8.09 11 6.72 - - - -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 115 44 -2.25 44 23 31 66 46 25 14
Total Preferred & Common Equity		 115 44 -2.25 44 23 31 66 46 25 14
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 115 44 -2.25 44 23 31 66 46 25 14
Common Stock		 505 381 292 381 195 153 142 84 38 17
Retained Earnings		 -391 -337 -295 -337 -173 -123 -76 -38 -13 -3.09
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 0.00 0.00 -0.00 0.00 -0.00 -0.05 -0.01 -

Quarterly Balance Sheets for Pulse Biosciences

This table presents Pulse Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 133 93 40 49 66 75 70 88
Total Current Assets		 121 80 27 36 52 60 55 71
Cash & Equivalents		 119 79 26 35 50 59 54 69
Inventories, net		 0.03 - - - - - - 0.75
Prepaid Expenses		 1.60 1.38 1.04 0.96 1.24 1.21 0.85 1.24
Plant, Property, & Equipment, net		 1.06 1.22 1.31 1.40 1.65 1.76 1.87 2.29
Total Noncurrent Assets		 11 11 12 12 13 13 13 14
Goodwill		 2.79 2.79 2.79 2.79 2.79 2.79 2.79 2.79
Intangible Assets		 1.05 1.39 1.55 1.72 2.05 2.22 2.38 2.72
Other Noncurrent Operating Assets		 7.57 7.23 7.53 7.41 7.83 8.04 8.23 8.62
Total Liabilities & Shareholders' Equity		 133 93 40 49 66 75 70 88
Total Liabilities		 15 14 13 13 14 14 81 81
Total Current Liabilities		 7.76 6.74 5.96 5.08 5.43 5.61 6.99 7.00
Accounts Payable		 2.37 1.73 1.64 1.71 1.41 1.79 2.16 2.02
Accrued Expenses		 3.98 3.82 3.18 2.27 3.00 2.84 3.09 3.98
Other Current Liabilities		 1.41 1.19 1.15 1.10 1.02 0.98 0.94 0.86
Total Noncurrent Liabilities		 7.17 7.17 7.50 7.80 8.37 8.64 74 74
Other Noncurrent Operating Liabilities		 7.17 7.17 7.50 7.80 8.37 8.64 8.90 9.38
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 118 79 27 36 52 61 -11 6.19
Total Preferred & Common Equity		 118 79 27 36 52 61 -11 6.19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 118 79 27 36 52 61 -11 6.19
Common Stock		 526 450 385 383 377 375 294 292
Retained Earnings		 -407 -371 -358 -347 -325 -314 -305 -286
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Pulse Biosciences

This table displays calculated financial ratios and metrics derived from Pulse Biosciences' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -100.00% -50.63% 0.00% 0.00% -100.00% 80.57% 263.24% 0.00% 0.00%
EBITDA Growth		 -30.00% 25.28% 8.33% -26.58% -3.28% -30.08% -48.23% -180.30% -133.40% 0.00%
EBIT Growth		 -29.11% 24.95% 7.87% -26.12% -4.19% -27.72% -46.85% -168.62% -113.03% 0.00%
NOPAT Growth		 -29.11% 24.95% 7.87% -26.12% -4.19% -27.72% -46.85% -168.62% -113.03% 0.00%
Net Income Growth		 -26.95% 27.85% 8.10% -27.70% -6.13% -25.11% -46.85% -168.62% -238.60% 0.00%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -2.73% -27.17% -101.16% -132.43% 0.00%
Operating Cash Flow Growth		 -9.99% 29.72% 13.10% -52.97% -3.45% -43.06% -115.53% -37.71% -142.72% 0.00%
Free Cash Flow Firm Growth		 -29.47% 21.57% 27.53% -53.49% 0.31% -28.08% -48.38% -207.27% 0.00% 0.00%
Invested Capital Growth		 -63,420.00% -100.20% -66.32% 210.54% -54.69% -20.92% -14.82% -10.97% -11.49% 0.00%
Revenue Q/Q Growth		 0.00% 100.00% -54.93% 185.89% 100.00% -100.00% 1.59% 61.44% 100.00% 0.00%
EBITDA Q/Q Growth		 -16.36% -9.91% 10.57% -2.61% 2.06% -14.27% -0.72% -30.81% -16.92% 0.00%
EBIT Q/Q Growth		 -15.92% -9.52% 10.30% -2.57% 1.84% -13.81% -0.67% -29.96% -15.45% 0.00%
NOPAT Q/Q Growth		 -15.92% -9.52% 10.30% -2.57% 1.84% -13.81% -0.67% -29.96% -15.45% 0.00%
Net Income Q/Q Growth		 -16.15% -6.93% 9.61% -2.69% 0.08% -11.47% -0.67% -29.96% -23.19% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -6.60% 1.79% -25.36% -8.86% 0.00%
Operating Cash Flow Q/Q Growth		 -6.95% 3.46% 9.14% -6.79% -0.17% -9.23% -10.88% -17.42% -13.99% 0.00%
Free Cash Flow Firm Q/Q Growth		 -12.07% -1.76% 12.92% -6.11% 0.65% -11.17% 0.63% -35.20% 0.00% 0.00%
Invested Capital Q/Q Growth		 -3,340.82% -100.28% 19.06% 15.89% -22.42% -17.65% -4.28% 0.41% -2.70% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% -1,606.29% -38.79% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% -8,100.29% -4,362.13% 0.00% 0.00% -8,155.83% -9,935.22% -12,875.00% 0.00%
Operating Margin		 0.00% 0.00% -8,293.86% -4,443.86% 0.00% 0.00% -8,418.16% -10,351.01% -13,997.06% 0.00%
EBIT Margin		 0.00% 0.00% -8,293.86% -4,443.86% 0.00% 0.00% -8,418.16% -10,351.01% -13,997.06% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% -8,357.86% -4,489.42% 0.00% 0.00% -8,418.16% -10,351.01% -13,997.06% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 62.91%
Interest Burden Percent		 95.25% 96.87% 100.77% 101.03% 99.77% 97.95% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -809.40% -888.33% 0.00% 0.00% -358.13% -212.69% -70.27% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -656.71% -807.96% 0.00% 0.00% -335.06% -184.53% -41.72% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 459.51% 671.00% 0.00% 0.00% 291.28% 140.97% 21.42% 0.00%
Return on Equity (ROE)		 -67.31% -200.47% -349.89% -217.33% -185.90% -96.78% -66.85% -71.72% -48.86% -20.57%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -710.18% -990.89% -826.39% -531.94% -342.12% -201.08% -58.08% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -87.88% -131.91% 0.00% 0.00% -62.34% -67.16% -46.84% 0.00%
Return on Assets (ROA)		 0.00% 0.00% -88.56% -133.26% 0.00% 0.00% -62.34% -67.16% -46.84% 0.00%
Return on Common Equity (ROCE)		 -67.31% -200.47% -349.89% -217.33% -185.90% -96.78% -66.85% -71.72% -48.86% -20.57%
Return on Equity Simple (ROE_SIMPLE)		 -46.65% -95.15% 2,602.54% -178.37% -217.75% -152.82% -56.60% -55.59% -37.62% -20.57%
Net Operating Profit after Tax (NOPAT)		 -39 -31 -41 -44 -35 -34 -26 -18 -6.66 -3.13
NOPAT Margin		 0.00% 0.00% -5,805.70% -3,110.71% 0.00% 0.00% -5,892.71% -7,245.71% -9,797.94% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -17.49% -59.15% -152.69% -80.37% -64.86% -31.54% -23.07% -28.17% -28.55% 8.78%
Return On Investment Capital (ROIC_SIMPLE)		 -34.28% -68.76% - - - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 1,706.29% 138.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 1,993.57% 1,345.06% 0.00% 0.00% 4,494.39% 6,276.52% 5,022.06% 0.00%
R&D to Revenue		 0.00% 0.00% 2,977.00% 2,019.75% 0.00% 0.00% 3,868.39% 3,905.26% 8,097.06% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 6,687.57% 4,405.08% 0.00% 0.00% 8,518.16% 10,451.01% 14,097.06% 0.00%
Earnings before Interest and Taxes (EBIT)		 -56 -44 -58 -63 -50 -48 -38 -26 -9.52 -4.47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -55 -42 -57 -62 -49 -47 -36 -25 -8.76 -3.75
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 9.32 15.17 0.00 12.30 26.41 9.07 2.93 8.38 3.42 0.00
Price to Tangible Book Value (P/TBV)		 9.66 16.96 0.00 14.78 37.28 11.91 3.34 10.33 5.42 0.00
Price to Revenue (P/Rev)		 0.00 0.00 147.32 309.48 0.00 0.00 436.45 1,561.35 1,272.79 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 42.65 54.67 241.49 47.46 20.01 43.85 7.88 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 154.14 289.61 0.00 0.00 302.85 1,407.23 1,031.68 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 -29.32 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 -28.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -0.94 -0.70 -0.83 -0.86 -0.88 -0.87 -0.76 -0.51 -0.26
Leverage Ratio		 1.20 3.25 3.95 1.63 1.55 1.16 1.07 1.07 1.04 1.05
Compound Leverage Factor		 1.15 3.15 3.98 1.65 1.55 1.14 1.07 1.07 1.04 1.05
Debt to Total Capital		 0.00% 0.00% 103.53% 1.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 1.44% 1.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 102.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% -3.53% 98.79% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 -1.16 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 -0.08 0.46 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -1.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -1.62 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 -0.12 0.64 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -1.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 31.98 17.68 -6.11 4.91 10.30 7.72 24.85 58.59 49.96 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 11.88 6.76 10.39 4.30 2.95 5.92 19.42 17.39 16.40 6.06
Quick Ratio		 11.74 6.61 10.22 3.37 2.70 5.70 19.17 17.20 16.14 5.46
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -36 -28 -36 -49 -32 -32 -25 -17 -5.51 0.00
Operating Cash Flow to CapEx		 -29,074.40% -27,306.61% -11,723.94% -12,379.18% -8,019.27% -5,622.53% -8,657.97% -434.61% -12,579.69% -3,856.98%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.03 0.00 0.00 0.01 0.01 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.32 0.57 0.00 0.00 0.19 0.17 0.21 0.00
Accounts Payable Turnover		 0.00 0.00 5.34 0.85 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 68.41 428.52 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 -68.41 -428.52 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -3.18 -0.01 2.53 7.51 2.42 5.34 6.75 7.93 8.90 10
Invested Capital Turnover		 0.00 0.00 0.14 0.29 0.00 0.00 0.06 0.03 0.01 0.00
Increase / (Decrease) in Invested Capital		 -3.17 -2.54 -4.98 5.09 -2.92 -1.41 -1.18 -0.98 -1.16 0.00
Enterprise Value (EV)		 953 629 108 411 584 253 135 348 70 0.00
Market Capitalization		 1,071 673 103 439 605 279 195 386 87 0.00
Book Value per Share		 $1.87 $0.81 ($0.06) $1.20 $0.90 $1.48 $3.91 $2.81 $1.90 $1.81
Tangible Book Value per Share		 $1.80 $0.72 ($0.20) $1.00 $0.64 $1.13 $3.43 $2.28 $1.20 $0.48
Total Capital		 115 44 64 36 23 31 66 46 25 14
Total Debt		 0.00 0.00 66 0.44 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 65 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -118 -44 4.78 -28 -20 -25 -60 -38 -16 -3.61
Capital Expenditures (CapEx)		 0.13 0.12 0.40 0.44 0.44 0.61 0.28 2.55 0.06 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.64 -5.75 -4.06 -0.07 -5.72 -3.45 -2.33 -1.80 -0.75 -0.27
Debt-free Net Working Capital (DFNWC)		 109 39 57 29 15 22 57 36 16 3.34
Net Working Capital (NWC)		 109 39 56 28 15 22 57 36 16 3.34
Net Nonoperating Expense (NNE)		 14 12 18 20 15 13 11 7.67 2.86 -0.32
Net Nonoperating Obligations (NNO)		 -118 -44 4.78 -28 -20 -25 -60 -38 -16 -3.61
Total Depreciation and Amortization (D&A)		 1.18 1.21 1.36 1.16 1.10 0.64 1.17 1.03 0.76 0.72
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -579.43% -4.73% 0.00% 0.00% -522.20% -729.15% -1,100.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 8,154.71% 2,013.19% 0.00% 0.00% 12,837.22% 14,683.40% 23,010.29% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 8,023.71% 1,982.44% 0.00% 0.00% 12,837.22% 14,683.40% 23,010.29% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.92) ($0.88) ($1.72) ($2.28) ($2.14) ($2.26) ($2.20) ($1.73) ($0.86) ($0.37)
Adjusted Weighted Average Basic Shares Outstanding		 58.40M 48.04M 33.94M 29.80M 26.09M 20.83M 20.69M 16.84M 14.14M 7.57M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.28) ($2.14) ($2.26) ($2.20) ($1.73) ($0.86) ($0.37)
Adjusted Weighted Average Diluted Shares Outstanding		 67.27M 55.23M 37.59M 29.80M 26.09M 20.83M 20.69M 16.84M 14.14M 7.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.28) ($2.14) ($2.26) ($2.20) ($1.73) ($0.86) ($0.37)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 67.27M 55.23M 37.59M 27.96M 23.25M 20.75M 17.08M 14.75M 11.01M 7.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -39 -31 -41 -44 -35 -34 -26 -18 -6.66 -3.13
Normalized NOPAT Margin		 0.00% 0.00% -5,805.70% -3,110.71% 0.00% 0.00% -5,892.71% -7,245.71% -9,797.94% 0.00%
Pre Tax Income Margin		 0.00% 0.00% -8,357.86% -4,489.42% 0.00% 0.00% -8,418.16% -10,351.01% -13,997.06% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Pulse Biosciences

This table displays calculated financial ratios and metrics derived from Pulse Biosciences' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% -100.00% -101.07% -100.00%
EBITDA Growth		 -72.17% -63.33% -21.98% -15.14% -11.40% -45.43% 38.07% 27.34% 45.36% 44.36% -26.46%
EBIT Growth		 -69.99% -61.66% -21.36% -14.66% -11.01% -43.32% 37.58% 27.02% 44.64% 43.25% -26.29%
NOPAT Growth		 -69.99% -61.66% -21.36% -14.66% -11.01% -43.32% 37.58% 27.02% 44.64% 43.25% -26.29%
Net Income Growth		 -65.68% -62.45% -20.01% -14.86% -3.43% -29.75% 41.43% 29.19% 43.26% 40.34% -26.31%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -38.25% -34.83% 13.95% 8.77% -48.86% 14.85% 1.36% 28.23% 57.87% 37.25% 20.36%
Free Cash Flow Firm Growth		 -33.40% -76.52% -5.15% -2,351.07% -2,091.19% -447.44% 9.08% 93.26% 102.11% 92.82% 38.15%
Invested Capital Growth		 -158.99% -63,420.00% -94.43% -55.90% 35.46% -100.20% -17.22% -79.66% -87.25% -66.32% -67.22%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% -100.00%
EBITDA Q/Q Growth		 11.08% -49.49% -16.91% -10.78% 15.64% -11.65% -10.36% -7.18% -10.12% 52.45% -29.47%
EBIT Q/Q Growth		 10.94% -48.38% -16.45% -10.47% 15.30% -11.38% -10.02% -6.95% -9.34% 51.48% -28.62%
NOPAT Q/Q Growth		 10.94% -48.38% -16.45% -10.47% 15.30% -11.38% -10.02% -6.95% -9.34% 51.48% -28.62%
Net Income Q/Q Growth		 13.36% -52.88% -11.39% -12.29% 15.05% -12.94% -6.62% -1.11% -6.57% 49.02% -28.89%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -47.87% -1.33% -7.49% 14.16% -44.21% 35.33% -13.96% -40.06% 17.51% 25.08% 17.08%
Free Cash Flow Firm Q/Q Growth		 5.54% -39.43% -9.26% 7.30% -25.00% 16.94% -2,446.76% -175.31% 134.37% 86.21% -88.91%
Invested Capital Q/Q Growth		 73.96% -3,340.82% -87.32% -44.86% 28,140.00% -100.28% 0.34% 69.37% -59.09% 19.06% -75.34%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.08% 95.68% 92.86% 97.07% 95.50% 95.21% 93.90% 96.90% 102.50% 105.17% 100.08%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -77.86% -67.31% -70.28% -100.65% -332.14% -200.47% -135.34% -111.89% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -3,479.73% -2,478.88% -2,593.84% 0.00% -1,415.25% -496.19% -615.12% -710.18% -951.51%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -77.86% -67.31% -70.28% -100.65% -332.14% -200.47% -135.34% -111.89% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -50.86% 0.00% -58.30% -163.22% -117.25% 0.00% -75.70% -77.60% 478.37% 0.00% -1,045.79%
Net Operating Profit after Tax (NOPAT)		 -13 -14 -9.56 -8.21 -7.43 -8.77 -7.88 -7.16 -6.69 -6.12 -13
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.40% -6.41% -4.82% -7.48% -23.35% -15.96% -9.88% -7.48% -638.77% -26.29% -24.11%
Return On Investment Capital (ROIC_SIMPLE)		 -10.66% -12.35% - - - -19.78% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -18 -20 -14 -12 -11 -13 -11 -10 -9.56 -8.75 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -20 -13 -11 -10 -12 -11 -9.93 -9.26 -8.41 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 9.14 9.32 13.59 22.91 13.26 15.17 4.24 4.47 0.00 0.00 13.80
Price to Tangible Book Value (P/TBV)		 9.44 9.66 14.34 27.31 15.14 16.96 4.68 4.88 0.00 0.00 125.39
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 493.40 147.32 54.98
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 10,163.25 765.56 318.21 0.00 97.14 120.88 133.35 42.65 38.27
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 539.12 154.14 52.37
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -6.17 -29.32 10.52
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -6.09 -28.91 10.50
Financial Leverage		 -1.00 -1.02 -0.99 -0.97 -0.90 -0.94 -0.93 -0.88 -0.10 -0.70 -0.84
Leverage Ratio		 1.18 1.20 1.21 1.32 4.66 3.25 2.63 1.37 10.84 3.95 2.89
Compound Leverage Factor		 1.10 1.15 1.12 1.28 4.45 3.10 2.47 1.33 11.11 4.16 2.89
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 119.35% 103.53% 91.32%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.45% 1.44% 0.14%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 117.90% 102.09% 91.18%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -19.35% -3.53% 8.68%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.34 -1.16 -1.03
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.24 -0.08 0.06
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.33 -1.15 -1.03
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.87 -1.62 -1.44
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.33 -0.12 0.09
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.84 -1.60 -1.43
Altman Z-Score		 39.79 32.87 41.24 14.81 12.57 19.41 3.00 5.92 -4.76 -4.02 -3.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.58 11.88 11.93 4.57 7.06 6.76 9.50 10.68 7.86 10.39 10.17
Quick Ratio		 15.37 11.74 11.72 4.39 6.87 6.61 9.28 10.47 7.74 10.22 9.88
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -10 -11 -7.90 -7.23 -7.80 -6.24 -7.51 -0.29 0.39 -1.14 -8.26
Operating Cash Flow to CapEx		 -30,046.67% -17,252.83% -23,747.37% -28,948.28% -195,600.00% -15,772.09% -45,595.65% -57,512.50% -16,846.15% -19,426.83% -17,148.39%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 40.34
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.73
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.12 0.32 0.66
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.75 5.18 3.91 5.34 5.03
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.05
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 77.20
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 485.44 70.47 93.38 68.41 72.55
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -93.38 -68.41 13.70
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.83 -3.18 0.10 0.77 1.40 -0.01 1.76 1.75 1.04 2.53 2.13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.14 0.36
Increase / (Decrease) in Invested Capital		 -2.23 -3.17 -1.66 -0.98 0.37 -2.54 -0.37 -6.86 -7.09 -4.98 -4.36
Enterprise Value (EV)		 963 953 996 592 446 629 171 212 138 108 81
Market Capitalization		 1,082 1,071 1,075 618 481 673 221 271 126 103 85
Book Value per Share		 $1.76 $1.87 $1.29 $0.49 $0.66 $0.81 $0.95 $1.61 ($0.29) ($0.06) $0.17
Tangible Book Value per Share		 $1.70 $1.80 $1.22 $0.41 $0.58 $0.72 $0.86 $1.47 ($0.43) ($0.20) $0.02
Total Capital		 118 115 79 27 36 44 52 61 55 64 71
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 66 66 65
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 65 65 65
Net Debt		 -119 -118 -79 -26 -35 -44 -50 -59 12 4.78 -4.06
Capital Expenditures (CapEx)		 0.05 0.05 0.04 0.03 0.01 0.04 0.02 0.02 0.04 0.04 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.13 -8.64 -5.36 -4.92 -4.12 -5.75 -4.20 -4.40 -5.34 -4.06 -4.90
Debt-free Net Working Capital (DFNWC)		 113 109 74 21 31 39 46 54 49 57 64
Net Working Capital (NWC)		 113 109 74 21 31 39 46 54 48 56 64
Net Nonoperating Expense (NNE)		 4.16 5.20 3.12 3.17 2.71 3.16 2.69 2.75 3.11 3.08 5.42
Net Nonoperating Obligations (NNO)		 -119 -118 -79 -26 -35 -44 -50 -59 12 4.78 -4.06
Total Depreciation and Amortization (D&A)		 0.28 0.29 0.29 0.30 0.30 0.30 0.30 0.30 0.30 0.34 0.34
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,086.33% -579.43% -315.58%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19,045.70% 8,154.71% 4,137.86%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 18,732.81% 8,023.71% 4,131.55%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.25) ($0.33) ($0.21) ($0.20) ($0.18) ($0.18) ($0.19) ($0.22) ($0.26) ($0.21) ($0.49)
Adjusted Weighted Average Basic Shares Outstanding		 67.13M 58.40M 61.07M 57.18M 55.17M 49.74M 54.92M 44.51M 37.39M 33.94M 37.16M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.49)
Adjusted Weighted Average Diluted Shares Outstanding		 67.27M 67.27M 61.52M 61.29M 55.23M 55.23M 54.99M 54.90M 37.64M 37.59M 37.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 67.27M 67.27M 61.52M 61.29M 55.23M 55.23M 54.99M 54.90M 37.64M 37.59M 37.23M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -14 -9.56 -8.21 -7.43 -8.77 -7.88 -7.16 -6.69 -6.12 -13
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Pulse Biosciences' Financials

When does Pulse Biosciences's financial year end?

According to the most recent income statement we have on file, Pulse Biosciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Pulse Biosciences' net income changed over the last 9 years?

Pulse Biosciences' net income appears to be on an upward trend, with a most recent value of -$53.59 million in 2024, rising from -$2.81 million in 2015. The previous period was -$42.21 million in 2023.

What is Pulse Biosciences's operating income?
Pulse Biosciences's total operating income in 2024 was -$56.26 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $56.26 million
How has Pulse Biosciences revenue changed over the last 9 years?

Over the last 9 years, Pulse Biosciences' total revenue changed from $0.00 in 2015 to $0.00 in 2024, a change of 0.0%.

How much debt does Pulse Biosciences have?

Pulse Biosciences' total liabilities were at $17.60 million at the end of 2024, a 19.0% increase from 2023, and a 2,566.4% increase since 2015.

How much cash does Pulse Biosciences have?

In the past 9 years, Pulse Biosciences' cash and equivalents has ranged from $2.09 million in 2016 to $118.04 million in 2024, and is currently $118.04 million as of their latest financial filing in 2024.

How has Pulse Biosciences' book value per share changed over the last 9 years?

Over the last 9 years, Pulse Biosciences' book value per share changed from 1.81 in 2015 to 1.87 in 2024, a change of 3.4%.


Related Companies

This page (NASDAQ:PLSE) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored